Ann H. Partridge, MD, MPH, FASCO, is a professor of medicine at Harvard Medical School, and vice chair of medical oncology at Dana-Farber Cancer Institute, where she serves as director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer.More recently, she has collaborated to develop and study interventions to improve outcomes in young adult cancer survivors and worked with basic investigators to identify molecular differences in tumors found in young patients and potential biomarkers of long-term effects.She is a medical oncologist focusing on the care of women with breast cancer and has a particular interest in the psychosocial, behavioral and communication issues in breast cancer care and treatment.She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, and the Edward J. Benz Jr. Award for Advancing the Careers of Women Faculty.She is helping enroll patients in the study, called POSITIVE.Through a developmental research cohort, she has characterized many of the complex medical and psychological challenges facing young women with breast cancer and has set the stage for future research in this understudied population.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Harvard Medical School
Eighty-seven percent — or 780 of 897 women with breast cancer at 11 academic and community medical centers — reported BRCA testing by a year after their disease diagnosis, while only 13 percent or 117 women had not undergone the genetic testing. In the United States, breast cancer is the top cancer diagnosed in females under 40. Those diagnosed with the cancer at age 50 or below are recommended by guidelines from the National Comprehensive Cancer Network to undergo the gene tests, as carriers of BRCA mutations are more prone to developing early-onset breast cancer. "Given that knowledge and concern about genetic risk influence surgical decisions and may affect systemic therapy trial eligibility, all young women with breast cancer should be counseled and offered genetic testing, consistent with the National Comprehensive Cancer Network guidelines," said the authors led by Dr. Ann Partridge of the Dana-Farber Cancer Institute in Boston. The authors have found that the frequency of gene testing even increased over time.